Lyvgen Biopharma Holdings Limited

This early-stage trial tested an experimental drug called LVGN6051, which activates immune cells by targeting CD137, both alone and combined with the approved immunotherapy Keytruda. The study involved 105 adults with advanced or metastatic cancers that had spread. The main goal …

This early-phase trial tested a combination of two drugs—LVGN6051, an experimental immune therapy, and anlotinib, a targeted cancer pill—in 39 adults with advanced soft tissue sarcoma that had stopped responding to standard treatments. The main goals were to check safety and find…

This early-stage study tested a new drug called LVGN7409, which boosts the immune system to fight cancer. It was given alone or with other immune-boosting drugs to 66 adults with advanced cancers that had stopped responding to standard treatments. The main goal was to find the sa…